Branded Legacy Partners with McMaster University to Advance Addiction Treatment Solutions
TL;DR
Branded Legacy gains a strategic advantage by partnering with McMaster University to accelerate product evaluations and regulatory approvals in the addiction treatment market.
The collaboration combines McMaster's clinical trial expertise with Bio-Legacy's scientific experience to develop rigorous evaluation protocols for addiction interventions.
This partnership aims to reduce overdose deaths and promote long-term recovery through accessible, cost-effective addiction treatment solutions.
Branded Legacy's intranasal delivery technology enables precise dosing for opioid overdose reversal and potential vaccine applications.
Found this article helpful?
Share it with your network and spread the knowledge!
Branded Legacy, Inc. has announced that its wholly owned subsidiary, Bio-Legacy Evaluative Group, has entered into a strategic partnership with McMaster University to evaluate innovative products for populations affected by addictions. The collaboration combines McMaster's expertise in addiction medicine, clinical trials, and guideline development with Bio-Legacy's real-world scientific experience to advance rigorous evaluations, clinical trials, and regulatory submissions. This partnership supports the development of accessible, cost-effective interventions aimed at reducing overdose deaths, minimizing drug-related harms, and promoting long-term recovery.
The collaboration represents a significant step forward in addressing the ongoing addiction crisis through evidence-based approaches that bridge academic research with practical application. Branded Legacy is a holdings company focused on health and wellness, developing innovative solutions to combat addiction by preventing overdoses and supporting recovery. The company's patented intranasal naloxone delivery device enhances accessibility and dosing precision for opioid overdose treatment. For more information about the company's initiatives, visit https://BrandedLegacy.com.
The platform also enables nasal delivery of vaccines and other medications, opening opportunities in global markets for rapid pandemic response and improved access in underserved regions. This partnership with McMaster University aligns with the company's mission to drive shareholder value while addressing critical public health challenges through scientific innovation and strategic collaborations. The full press release detailing this partnership can be accessed at https://ibn.fm/8ojxr. This collaboration represents a meaningful advancement in the field of addiction medicine, potentially leading to more effective treatments and improved outcomes for individuals struggling with substance use disorders.
Curated from InvestorBrandNetwork (IBN)
